| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $373,039 | 9 | 12 |
Sells | $14,269,201 | 66 | 88 |
| Heron Patrick J | director | 9 | $373,039 | 0 | $0 | $373,039 |
| Vairavan Latha | SVP Chief Financial Officer | 0 | $0 | 2 | $3,450 | $-3,450 |
| Topper David Joseph | Chief Financial Officer | 0 | $0 | 1 | $151,698 | $-151,698 |
| Gilbert Halley E | director | 0 | $0 | 1 | $455,442 | $-455,442 |
| LIN SUE-JEAN | director | 0 | $0 | 1 | $777,956 | $-777,956 |
| Krishnamohan Neha | director | 0 | $0 | 1 | $939,494 | $-939,494 |
| Edwards Larry Todd | See Remarks | 0 | $0 | 4 | $955,637 | $-955,637 |
| Matsuda Masaru | See Remarks | 0 | $0 | 9 | $1.22M | $-1.22M |
| Welgus Howard G. | director | 0 | $0 | 12 | $2.06M | $-2.06M |
| Burnett Patrick | See Remarks | 0 | $0 | 19 | $2.83M | $-2.83M |
| Watanabe Todd | See Remarks | 0 | $0 | 9 | $4.03M | $-4.03M |
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.
Over the last 12 months, insiders at Arcutis Biotherapeutics, Inc. have bought $373,039 and sold $14.27M worth of Arcutis Biotherapeutics, Inc. stock.
On average, over the past 5 years, insiders at Arcutis Biotherapeutics, Inc. have bought $1.46M and sold $6.28M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Heron Patrick J (director) — $373,039.
The last purchase of 2,646 shares for transaction amount of $34,610 was made by Heron Patrick J (director) on 2025‑06‑13.
| 2026-01-05 | Sale | Burnett Patrick | See Remarks | 2,490 0.002% | $28.98 | $72,166 | -10.10% | |
| 2026-01-02 | Sale | Welgus Howard G. | director | 10,000 0.0081% | $28.96 | $289,606 | -8.49% | |
| 2025-12-31 | Sale | Burnett Patrick | See Remarks | 1,697 0.0014% | $29.20 | $49,560 | -8.49% | |
| 2025-12-15 | Sale | Burnett Patrick | See Remarks | 11,500 0.0094% | $28.94 | $332,851 | -1.78% | |
| 2025-12-01 | Sale | Matsuda Masaru | See Remarks | 1,657 0.0013% | $30.23 | $50,091 | -4.48% | |
| 2025-12-01 | Sale | Welgus Howard G. | director | 10,000 0.0081% | $30.21 | $302,133 | -4.48% | |
| 2025-11-24 | Sale | Watanabe Todd | See Remarks | 48,945 0.0411% | $30.36 | $1.49M | -5.21% | |
| 2025-11-24 | Sale | LIN SUE-JEAN | director | 25,272 0.0215% | $30.78 | $777,956 | -5.21% | |
| 2025-11-21 | Sale | Watanabe Todd | See Remarks | 1,055 0.0009% | $30.00 | $31,650 | -0.72% | |
| 2025-11-20 | Sale | Gilbert Halley E | director | 16,532 0.0136% | $27.55 | $455,442 | +7.18% | |
| 2025-11-19 | Sale | Matsuda Masaru | See Remarks | 2,550 0.0021% | $28.29 | $72,135 | +4.97% | |
| 2025-11-13 | Sale | Krishnamohan Neha | director | 40,504 0.0336% | $23.20 | $939,494 | +26.95% | |
| 2025-11-06 | Sale | Edwards Larry Todd | See Remarks | 29,131 0.0236% | $25.16 | $732,927 | +15.38% | |
| 2025-11-06 | Sale | Burnett Patrick | See Remarks | 17,250 0.0135% | $24.18 | $417,145 | +15.38% | |
| 2025-11-05 | Sale | Burnett Patrick | See Remarks | 3,864 0.003% | $23.72 | $91,643 | +18.74% | |
| 2025-11-03 | Sale | Watanabe Todd | See Remarks | 11,547 0.0092% | $24.72 | $285,399 | +15.35% | |
| 2025-11-03 | Sale | Matsuda Masaru | See Remarks | 7,208 0.0057% | $24.72 | $178,156 | +15.35% | |
| 2025-11-03 | Sale | Burnett Patrick | See Remarks | 2,622 0.0021% | $24.72 | $64,806 | +15.35% | |
| 2025-11-03 | Sale | Welgus Howard G. | director | 10,000 0.0082% | $25.27 | $252,669 | +15.35% | |
| 2025-11-03 | Sale | Vairavan Latha | SVP Chief Financial Officer | 88 <0.0001% | $24.72 | $2,175 | +15.35% |
| Watanabe Todd | See Remarks | 740537 0.6046% | $19.4M | 3 | 60 | +14.82% |
| Topper David Joseph | Chief Financial Officer | 182774 0.1492% | $4.79M | 0 | 2 | |
| Matsuda Masaru | See Remarks | 150641 0.123% | $3.95M | 2 | 20 | +18.84% |
| Edwards Larry Todd | See Remarks | 150193 0.1226% | $3.94M | 1 | 6 | 0% |
| Burnett Patrick | See Remarks | 94120 0.0768% | $2.47M | 0 | 36 | |
| Welgus Howard G. | director | 69744 0.0569% | $1.83M | 0 | 48 | |
| Vairavan Latha | SVP Chief Financial Officer | 64927 0.053% | $1.7M | 0 | 2 | |
| Heron Patrick J | director | 27448 0.0224% | $719,137.60 | 12 | 0 | <0.0001% |
| LIN SUE-JEAN | director | 26735 0.0218% | $700,457.00 | 0 | 1 | |
| Gilbert Halley E | director | 22123 0.0181% | $579,622.60 | 0 | 1 | |
| Krishnamohan Neha | director | 22123 0.0181% | $579,622.60 | 0 | 1 | |
| Frazier Life Sciences VIII, L.P. | 10 percent owner | 8764232 7.1549% | $229.62M | 2 | 0 | +140.17% |
| ORBIMED ADVISORS LLC | 4267564 3.484% | $111.81M | 2 | 0 | +10.62% | |
| SILVERSTEIN JONATHAN | 4267564 3.484% | $111.81M | 2 | 0 | +10.62% | |
| Bain Capital Life Sciences Investors, LLC | 10 percent owner | 3979292 3.2486% | $104.26M | 1 | 0 | +5.03% |
| CHAUDHURI BHASKAR | director | 841391 0.6869% | $22.04M | 0 | 9 | |
| OrbiMed Capital GP VII LLC | 415142 0.3389% | $10.88M | 0 | 2 | ||
| OSBORNE DAVID W | Chief Technical Officer | 268854 0.2195% | $7.04M | 0 | 10 | |
| Moore Matthew Richard | SVP and Chief Business Officer | 145505 0.1188% | $3.81M | 0 | 3 | |
| Lock Kenneth A. | Chief Commercial Officer | 63429 0.0518% | $1.66M | 0 | 6 | |
| Turney Patricia A. | SVP, Operations | 62862 0.0513% | $1.65M | 0 | 6 | |
| Burrows Scott L | Chief Financial Officer | 59115 0.0483% | $1.55M | 0 | 6 | |
| Smither John W | Chief Financial Officer | 46321 0.0378% | $1.21M | 0 | 7 | |
| Curran Terrie | director | 10139 0.0083% | $265,641.80 | 0 | 1 |
$11,588,217 | 69 | 42.07% | $2.9B | |
$104,428,685 | 44 | 22.55% | $3.53B | |
$148,770,544 | 34 | 80.63% | $3.33B | |
$5,066,938 | 27 | 26.38% | $3.23B | |
$61,703,557 | 26 | 40.25% | $3.09B | |
$150,253,463 | 26 | -52.83% | $3.4B | |
Arcutis Biotherapeutics, Inc. (ARQT) | $137,061,250 | 16 | 23.01% | $3.21B |
$92,580,864 | 14 | -1.28% | $3.03B | |
$1,248,715 | 10 | 5.66% | $3.34B | |
$45,445,266 | 9 | -24.96% | $3.05B | |
$1,711,150 | 9 | 31.59% | $3.64B | |
$32,575,266 | 8 | 37.03% | $2.9B | |
$91,589,325 | 7 | -6.97% | $2.91B | |
$182,500,000 | 6 | 29.00% | $3.91B | |
$461,215 | 5 | 10.35% | $3.78B | |
$24,000,085 | 4 | 33.26% | $2.88B | |
$142,493,653 | 3 | 4.30% | $3.09B | |
$50,990,767 | 2 | 19.79% | $3.84B | |
$9,900,000 | 1 | -7.19% | $3.16B |
| Increased Positions | 123 | +48.62% | 10M | +7.57% |
| Decreased Positions | 110 | -43.48% | 11M | -8.24% |
| New Positions | 33 | New | 2M | New |
| Sold Out Positions | 21 | Sold Out | 2M | Sold Out |
| Total Postitions | 266 | +5.14% | 127M | -0.67% |
| Jennison Associates Llc | $355,369.00 | 10.04% | 12.25M | +1M | +10.3% | 2025-09-30 |
| Rubric Capital Management Lp | $311,734.00 | 8.81% | 10.75M | 0 | 0% | 2025-09-30 |
| Suvretta Capital Management, Llc | $303,862.00 | 8.59% | 10.48M | -1M | -9.17% | 2025-09-30 |
| Frazier Life Sciences Management, L.P. | $286,361.00 | 8.09% | 9.87M | 0 | 0% | 2025-09-30 |
| Blackrock, Inc. | $248,646.00 | 7.03% | 8.57M | +41,234 | +0.48% | 2025-09-30 |
| Vanguard Group Inc | $207,237.00 | 5.86% | 7.15M | +96,991 | +1.38% | 2025-09-30 |
| Polar Capital Holdings Plc | $153,664.00 | 4.34% | 5.3M | +292,279 | +5.84% | 2025-09-30 |
| State Street Corp | $134,598.00 | 3.8% | 4.64M | +114,378 | +2.53% | 2025-09-30 |
| Gilder Gagnon Howe & Co Llc | $128,444.00 | 3.63% | 4.43M | +273,345 | +6.58% | 2025-09-30 |
| Morgan Stanley | $124,015.00 | 3.51% | 4.28M | -38,136 | -0.88% | 2025-09-30 |